These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10491719)

  • 1. [Screening for colorectal cancer with an immunological fecal occult blood test].
    Fernández JL; Gallegos M; Brochero A; Arévalo C; Piccioni H; Gutiérrez Galiana H
    Acta Gastroenterol Latinoam; 1999; 29(2):73-8. PubMed ID: 10491719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal occult blood testing: a false sense of security?
    Schnell T; Aranha GV; Sontag SJ; Tode R; Reid S; Chejfec G; Karpf J; Levine G
    Surgery; 1994 Oct; 116(4):798-802; discussion 802-3. PubMed ID: 7940181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital fecal occult blood testing in the ambulatory urology clinic.
    Goetzl MA; Outman JE; Griebling TL; Holzbeierlein JM; Weigel JW; Thrasher JB
    J Am Coll Surg; 2008 Jan; 206(1):144-7. PubMed ID: 18155580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better acceptance of Fecal Occult Blood Test (FOBT) for colorectal cancer screening during hospitalization.
    Keller R; Schätzle A; Flieger D; Christl SU; Fischbach W
    Z Gastroenterol; 2003 Jul; 41(7):655-8. PubMed ID: 12858236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
    Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
    Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
    Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
    Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.
    Stokamer CL; Tenner CT; Chaudhuri J; Vazquez E; Bini EJ
    J Gen Intern Med; 2005 Mar; 20(3):278-82. PubMed ID: 15836533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer test use--Maryland, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project.
    Chen TH; Yen MF; Lai MS; Koong SL; Wang CY; Wong JM; Prevost TC; Duffy SW
    Cancer; 1999 Oct; 86(7):1116-28. PubMed ID: 10506694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre.
    Manus B; Brägelmann R; Armbrecht U; Stolte M; Stockbrügger RW
    Eur J Cancer Prev; 1996 Feb; 5(1):49-55. PubMed ID: 8664809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
    Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
    Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Lieberman N; Klang S; Niv Y
    Am J Gastroenterol; 2009 Apr; 104(4):933-8. PubMed ID: 19293792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.